ASP Reporting Could Prompt Changes In Manufacturer Contracts With PBMs
Executive Summary
The Centers for Medicare & Medicaid Services' reporting requirements for average sales price could necessitate changes to contracts between manufacturers and purchasers, Schering-Plough Legal Director David Ralston suggested Aug. 3 during a Healthcare Marketplace audioconference on sales price reporting
You may also be interested in...
Distribution Fees Remain Concern In ASP Reporting Despite CMS Clarification
The Centers for Medicare & Medicaid Services' position that bona fide service fees paid by manufacturers to wholesalers are exempt from average sales price calculations may not resolve problems with the fee-for-service distribution model, Sidley Austin Brown & Wood attorney William Sarraille said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials